AZ 14145845

Product Description

AZ 14145845 is a potent, and highly selective dual Mer/Axl kinase inhibitor (pIC₅₀ = 7 nM and 7.8 nM in pAxl and pMer, respectively). In vivo, AZ 14145845 shows dose-dependent reduction of tumor growth in the Mer and Axl kinase Ba/F3 tumor xenograft model. AZ 14145845 combined with anti-PD1 antibodies and ionizing radiation increases survival in mice with tumors derived from MC38 cells in vivo. AZ 14145845 is orally bioavailable.

Solubility

Preparing Stock Solutions for AZ 14145845

The following data is based on the product molecular weight 561.69

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.78 mL	8.90 mL	17.80 mL
5 mM	0.36 mL	1.78 mL	3.56 mL
10 mM	0.18 mL	0.89 mL	1.78 mL
50 mM	0.04 mL	0.18 mL	0.36 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• McCoull Optimization of an Imidazo[1,2.a]pyridine series to afford highly selective type I1/2 Dual Mer/Axl kinase inhibitors with in vivo efficacy. J.Med.Chem. 2021 PMID: 34478292